Literature DB >> 32095276

Dystonia in Ataxia Telangiectasia: A Case Report with Novel Mutations.

Majid Zaki-Dizaji1,2, Mohammad Tajdini3, Fatemeh Kiaee2, Hossein Shojaaldini3, Reza Shervin Badv3, Hassan Abolhassani2,4, Asghar Aghamohammadi2.   

Abstract

Ataxia telangiectasia (A-T) is a common, genetically inherited cause of early childhood-onset ataxia that is classically characterized by progressive cerebellar malfunction, oculocutaneous telangiectasia, genome instability, and immunodeficiency. There is vast phenotype variation in patients with A-T and recently, dystonia, an extrapyramidal movement disorder. Here, we report the case of a 10-year-old girl who had experienced repeated diarrhea and mild gait ataxia since the age of two years. At age seven, ataxia and ocular telangiectasia were evident and immunoglobulin level assessment showed hyper IgM immune phenotype, thus a diagnosis of A-T was made based on clinical and laboratory findings, and she was started on intravenous immunoglobulin therapy. Generalized dystonia appeared when she was 10-years-old. Molecular analysis revealed two heterozygous mutations, c.6259delG and c.6658C>T, in the ATM gene of which one (c.6259delG) is novel. Dystonia can be part of the clinical picture in the A-T disorder and may even mask ataxia. This should be considered as a major feature mainly in variant A-T, which may occur without general ataxia and may be misdiagnosed in adults with primary dystonia. The OMJ is Published Bimonthly and Copyrighted 2020 by the OMSB.

Entities:  

Keywords:  Ataxia Telangiectasia; Dystonia; Mutation

Year:  2020        PMID: 32095276      PMCID: PMC7024809          DOI: 10.5001/omj.2020.11

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


Introduction

Ataxia telangiectasia (A-T) [OMIM #208900] is an autosomal recessive multisystem disorder that is typically characterized by progressive cerebellar ataxia, oculocutaneous telangiectasia, variable immunodeficiency, increased alpha-fetoprotein levels, and hypersensitivity to ionizing radiations. A-T occurs at a frequency ranging from one in 40 000 to one in 100 000 births worldwide and ATM [OMIM *607585], an important player in DNA damage response/repair, is the only gene known to be associated with this disease.[1] There is a wide spectrum of phenotypic manifestations in patients with A-T. Recently, there is growing evidence that ATM mutations, can manifest generalized or focal dystonia with or without of the classical signs of A-T.[2,3] Here, we report a patient with classical A-T phenotype, hyper immunoglobulin (IgM) immune phenotype, and generalized dystonia, and literature review of reported cases with dystonia.

Case report

The 10-year-old girl was born to non-consanguineous, healthy, Iranian parents after an uneventful gestation and delivery. Her older sister was healthy, and there was no family history of neurological disease or malignancy. The first symptom that was noticed by parents was repeated diarrhea, which started when she was six months old until she turned two years old. At that time, inflammatory bowel disease was diagnosed by physicians based on diarrhea, failure to thrive and underweight, and the results of laboratory tests. She walked at about 16 months old, but after eight months (aged two years old), she manifested mild gait ataxia (abnormal swaying of the head and trunk). Her walk has improved since her parents started occupational therapy and her speech, fine motor and social skills were normal, but diarrhea continued. By the age of five years, cerebellar ataxia had progressed, and her speech had become dysarthric. At seven years old, when she was referred to our hospital, she had lost the ability of independent ambulation, and ocular telangiectasia was evident. Diagnosis of A-T was made based on clinical and laboratory findings and she was started on intravenous immunoglobulin therapy (IVIG). Laboratory finding showed serum IgG 5 mg/dL (normal: 800–1600), IgM 208 mg/dL (normal: 40–230), IgA 1 mg/dL (normal: 70–400), IgE 1 mg/dL (normal: up to 52); serum alpha-fetoprotein (AFP) levels 104.7 IU/mL (normal: < 5.5); and increased induced radiosensitivity as assessed by the G2 chromosomal radiosensitivity assay [Figure 1].
Figure 1

G2-chromosomal radiosensitivity assay results in a patient with ataxia telangiectasia and her parents. Individual radiosensitivity (IRS) estimated as IRS = [1-(G2caf-G2)/G2caf] × 100%.

G2-chromosomal radiosensitivity assay results in a patient with ataxia telangiectasia and her parents. Individual radiosensitivity (IRS) estimated as IRS = [1-(G2caf-G2)/G2caf] × 100%. When the patient was 10-years-old, she was no longer able to walk and received granulocyte-colony stimulating factor (G-CSF, two times) and antibiotic prophylaxis due to neutropenia and lymphadenopathy granulomatous. During this year, she experienced brief episodes of involuntary head extension and rotation, and her cervical dystonia worsened and extended to the limbs and trunk, mostly on the right side, causing an abnormal posture. Brain magnetic resonance imaging showed mild cerebral atrophy, mainly in the lower cerebellar hemisphere. The cerebellar vermis was intact, whereas the fourth ventricle showed some dilation. Therapeutic trials using trihexyphenidyl HCl and subsequently baclofen were initiated but were both ineffective. However, trihexyphenidyl with clonazepam relatively reduced the symptoms. Whole exome sequencing identified a compound heterozygous mutation in the ATM gene (c.6259delG and c.6658C>T) and was confirmed by Sanger sequencing in the patient and her parents. Both variants were located in the FAT domain (the name derived from FRAP, ATM, and TRRAP) of the ATM protein (p.Glu2087LysfsTer and p.Gln2220Ter; [Figure 2]). Bioinformatical tools support the pathological involvement of these variants (frequency: 0 in all databases, combined annotation-dependent depletion (CADD) scores: 35.00 and 45.00, respectively, and the mutation significance cutoff of ATM: 0.001).
Figure 2

Genetic study of ATM in ataxia telangiectasia patient. (a) Pedigree of the patient. (b) Confirmatory Sanger sequencing of proband for identified variants of the ATM gene. (c) Representation of mutation on ATM protein domains showing defect on FAT domain at amino acids region 1960 to 2566.

Genetic study of ATM in ataxia telangiectasia patient. (a) Pedigree of the patient. (b) Confirmatory Sanger sequencing of proband for identified variants of the ATM gene. (c) Representation of mutation on ATM protein domains showing defect on FAT domain at amino acids region 1960 to 2566.

Discussion

Biallelic mutations in ATM are associated with classical and milder forms (variant A-T) of A-T. The variant A-T does not present the cardinal features of the disease, or they become apparent only later in life with incomplete, atypical, and highly variable manifestations.[2,4] The neurological aspects of A-T are unfortunately still poorly understood, and is the main aspect of the disease and is not recapitulated in mice with complete deficiency of the murine ATM ortholog.[1] Impairment of the extrapyramidal movement system with signs including dystonia, myoclonus, chorea, parkinsonism, and both postural, rest, and kinetic tremor is also common among patients with A-T.[2,3] Recently, reports of different types of dystonia related to ATM gene mutations have attracted great attention [Table 1, 2, and 3].
Table 1

Dystonia frequency in classic and variant ataxia telangiectasia (A-T).

YearrefPatient number(age range, years)A-T casesPercentage (n)Frequent location of dystonia
1992[5]70 (2–42)Classic (62 cases) and variant (8)78% (55/70)Limbs, face, trunk, oromandibular
2009[2]13 (NA)Variant72% (8/11)-
2011[6]57 (2–19)Classic15.8% (9/57)-
2014[7]22 (2.7–19.7)Classic50% (10/20)-
2014[8]14 (21–36)Variant86% (12/14)Upper limbs, neck
Table 2

Dystonia reports in ataxia telangiectasia patients without ATM mutation analysis.

YearrefnClassic/ variantDystonia locationDystonia onset (age, years)First symptomAtaxia onsetCerebellar (number, age)AFP, ng/mLSerum IgsRadio sensitivity
1968[9]1CHEarly (19)NA14 mNANAIgA-LNA
1980[10]1CN, T, UL, LLEarly (9)N< 9 yNAHighIgA-LNA
1984[11]1VGEarly (16)N16 mNAnormalIgE-LNA
1987[12]2VDystoniaEarly (< 16)NANANASlightly highNormalYes (CSA, ICBA)
VULLate (28)NA12 mNASlightly highIgM-HYes (CSA, G2A)
1989[13]2VLEarly (7)Left handUpon walkingAtrophy (20 y)Slightly highNormal-
VDystonic gaitEarly (7)N4 yNAHighIgA-LYes (CSA, ICBA)
1993[14]1CLLEarly (~ 15)Left arm6 yAtrophy (17 y)HighIgA-LNA
1993[15]3CUL, NEarly (~ 2)ULs~ 2 yNormal (1, 20 m)HighIgA-LYes (ICBA)
1994[16]1CCC, T, UL, FEarly (4)N2 yAtrophy (6.5 y)HighIgA-LNormal (ICBA)
2002[17]1CN, T, ULEarly (12)NNAMild atrophy (13 y)HighNormalNA

Slightly high: 11-30, high: < 30 according to Ball and Waldmann studies.[18,19]

MN assay: S-G2 micronucleus assay, ICBA: induced chromosome breakage assay; CSA: colony survival assay; NA: not available; Ig: immunoglobulin; N: neck; T: trunk; UL: upper limb; LL: lower limb; CC: craniocervical; F: face; O: oromandibular; G: generalized; C: classic; V: variant; L: limbs; H: hand; RUL: right upper limb.

Table 3

Dystonia reports in ataxia telangiectasia cases with confirmed ATM mutation.

YearrefClassic/ variantCasesDystonia locationDystonia onset (age, years)First symptomAtaxia onset, yearsCerebellar(age, years)AFP (ng/mL)Serum IgRadio sensitivity
2008[20]V1N, LLEarly (14)N14Atrophy (42)Slightly highNormalNA
2009[21]V1CC, OEarly (15)NNo ataxiaMild atrophy (18)HighNANormal
2009–2014[22-24]V12N, L, C*Early (~ 12)CervicalLate-onset mild ataxiaMild atrophy (NA)HighNANA
2013[25]V3CREarly (~ 13)CervicalNo ataxiaNAHighNANA
2013[26]V1F, NEarly (~ 7)NANo ataxiaNormal (16)HighIgA-LowYes (MN assay)
2013[27]V1L, N, TEarly (2)LNo ataxiaNormal (48)HighNAYes (ICBA)
2013[28]V3N, L, TEarly (NA)CervicobrachialNo ataxiaNormal (NA)HighNAYes (CSA)
2013[29]V1DystoniaEarly (NA)NANo ataxiaAtrophy (41)HighIgA-LowYes (CSA)
2014[30]V1LL, TEarly (8)LL4Mild atrophy (7)HighIgE-LowNA
2015[31]V1N, T, OLate (45)NNo ataxiaNormal (45)HighIgA-LowNA
2015[32]V3N, RULLate (25)NNo ataxiaNormal (~ 40)HighNANA
N, RUL, TLate (30)N, RULNo ataxiaNormal (31)HighNANA
N, RULEarly (NA)N, RULNo ataxiaNAHighNANA
2016[33]C1NEarly (5)N, TChildhoodAtrophy (25)HighNANA

Ig: immunoglobulin; N: neck; NA: not available; T: trunk; UL: upper limb; LL: lower limb; CC: craniocervical; F: face; O: oromandibular; CR: cranial; L: limbs; H: hand; RUL: right upper limb; G: generalized; C: classic; V: variant; MN assay: S-G2 micronucleus assay; ICBA: induced chromosome breakage assay; CSA: colony survival assay. *prevalent ones.

Slightly high: 11-30, high: < 30 according to Ball and Waldmann studies.[18,19] MN assay: S-G2 micronucleus assay, ICBA: induced chromosome breakage assay; CSA: colony survival assay; NA: not available; Ig: immunoglobulin; N: neck; T: trunk; UL: upper limb; LL: lower limb; CC: craniocervical; F: face; O: oromandibular; G: generalized; C: classic; V: variant; L: limbs; H: hand; RUL: right upper limb. Ig: immunoglobulin; N: neck; NA: not available; T: trunk; UL: upper limb; LL: lower limb; CC: craniocervical; F: face; O: oromandibular; CR: cranial; L: limbs; H: hand; RUL: right upper limb; G: generalized; C: classic; V: variant; MN assay: S-G2 micronucleus assay; ICBA: induced chromosome breakage assay; CSA: colony survival assay. *prevalent ones. Dystonia is a movement disorder characterized by involuntary sustained or intermittent muscle contractions producing abnormal postures, repetitive movements, or both. Dystonic movements are usually manifested by twisting and may show a tremulous pattern. Before designating A-T as a distinct disease, dystonia was reported by Syllaba and Henner in three adolescent Czech siblings in association with ocular telangiectasia.[34] After this report, the non-primary (secondary) dystonia[35] was described in other articles repeatedly before [Table 2] and after [Table 3] identification of the ATM gene in patients with A-T. The dystonia frequency in patients with A-T vary in different case series [Table 1], and since myoclonic dystonia can easily be mistaken for chorea, the exact frequency is not known, but at least in variant A-T it accounts for 86% of cases[8] with prominent cervical, cranial, and brachial involvement [Table 1, 2, and 3]. Although dystonia has been manifested in both classic A-T and variant A-T at different ages with different body involvements, it has received great attention in the variant form, as dystonia is more frequent in this form of the disease and may in fact be the only symptom in variant A-T.[32] Currently, the treatment of dystonia in A-T patients remains symptomatic [Table 4]. Due to the marked heterogeneity of A-T, we have limited knowledge about the basis of individual responses to a given therapy.
Table 4

Reported treatment of dystonia in ataxia telangiectasia patients.

YearrefCasesClassic/VariantDystonia locationRelatively effective drug
1980[10]1CN, T, ULDiazepam (high dose), haloperidol
1991[36]1CN, T, ULBenzhexol
1994[16]1CCC, T, UL, FTrihexyphenidyl
2008[20]1VN, LL-
2009[21]1VCC, OBTX
2012[22]12VN, L, CRBTX, anticholinergic, diazepam
2013[25]3VNLevodopa/carbidopa
2013[26]1VG (F, N)-
2014[30]1CLL,TLevodopa
2015[31]1VN, T, OMethocarbamol (slightly)
2015[32]3VN, RULBTX, biperiden
2016[33]1CNBTX

N: neck; T: trunk; UL: upper limb; LL: lower limb; CC: craniocervical; F: face; O: oromandibular; CR: cranial; L: limbs; H: hand; RUL: right upper limb; C: classic; V: variant; BTX: botulinum toxin.

N: neck; T: trunk; UL: upper limb; LL: lower limb; CC: craniocervical; F: face; O: oromandibular; CR: cranial; L: limbs; H: hand; RUL: right upper limb; C: classic; V: variant; BTX: botulinum toxin. Dystonia, like other extrapyramidal features, is usually more prominent in late manifestations of classical A-T.[6] However, it may also be the initial or even the most prominent manifestation of A-T,[5,10] potentially masking ataxia symptoms.[10] This symptom mostly appears as an early-onset form of dystonia, and in variant forms without frank cerebellar involvement.[10,12,21,22,26-28,32] Therefore, it may mimic other forms of early-onset primary torsion dystonias[22] or present mildly without any notice.[32] In contrast to what we observed in our patient, dystonia is often associated with myoclonic jerks[8,10,22,27,30] and may be induced/worsened by specific motor or cognitive tasks and, similar to ataxia, it is progressive with age as expected in a neurodegenerative disorder.[6] The genotype-phenotype relation in dystonia of A-T patients is not well understood. It is accepted that mutations with severe loss of ATM protein (truncating/null mutations) cause severe disease, and mild mutations (usually missense) with a residual level of protein may cause milder forms or appear late in life. In classical A-T with truncating mutation, most neurological symptoms including dystonia are similar between patients.[6] However, in variant A-T, symptoms differ due to "milder" mutations, various combinations of compound heterozygous mutations, individual allelic expression pattern,[32] possible modifier genes, and alternative RNA splicing.[29] In addition, ATM enzymatic activity levels do not fully correlate with the milder phenotypes of variant A-T.[22] Accordingly, although the genotype and phenotype comparison in A-T contributes to improved insight into the pathological mechanisms in A-T, it remains to be studied further. Immunoglobulin class-switch recombination deficiency (CSR-D), previously known as hyper IgM syndrome, is a heterogeneous group of primary immunodeficiencies characterized by the presence of elevated or normal serum IgM levels and low or absent serum levels of the switched isotypes (IgG, IgA, and IgE). Elevated IgM is seen in 10–21% of A-T patients,[37] and due to mild or delayed neurologic symptoms may be misdiagnosed with CSR-D.[38] Most patients with classic A-T demonstrate immunoglobulin deficiency, but it is relatively infrequent in mild A-T forms,[2,8] but may still be helpful for diagnosis.[39] Based on previous publications, our patient is the first dystonic A-T with a class switching defect, causing hyper IgM immune phenotype.

Conclusion

Dystonia can be part of the clinical picture in A-T and may even mask ataxia. In clinical practice, early-onset dystonia with slow progression may be indicative of A-T. This is more important for the diagnosis of patients with the variant form of A-T, because, despite overall milder neurologic disease, the burden of malignancy remains high as for A-T, so patients will need surveillance of immunodeficiency and malignancies, as well as measures to lessen accumulating DNA damage from radiologic exposure and chemotherapeutic agents. Therefore, early-onset dystonia with cervical and brachial onset and prominent cranial involvement should be considered as a major feature of variant A-T, which may occur without general ataxia and may thus be misdiagnosed in adults with primary dystonia.
  38 in total

1.  Myoclonic head jerks and extensor axial dystonia in the variant form of ataxia telangiectasia.

Authors:  Gemma Cummins; Tania Jawad; Malcolm Taylor; Timothy Lynch
Journal:  Parkinsonism Relat Disord       Date:  2013-09-06       Impact factor: 4.891

2.  Myoclonic axial jerks for diagnosing atypical evolution of ataxia telangiectasia.

Authors:  Tojo Nakayama; Yuko Sato; Mitsugu Uematsu; Masatoshi Takagi; Setsuko Hasegawa; Satoko Kumada; Atsuo Kikuchi; Naomi Hino-Fukuyo; Yoji Sasahara; Kazuhiro Haginoya; Shigeo Kure
Journal:  Brain Dev       Date:  2014-06-18       Impact factor: 1.961

3.  Ataxia telangiectasia presenting as an extrapyramidal movement disorder and ocular motor apraxia without overt telangiectasia.

Authors:  A Churchyard; R Stell; F L Mastaglia
Journal:  Clin Exp Neurol       Date:  1991

4.  Novel ATM mutation in a German patient presenting as generalized dystonia without classical signs of ataxia-telangiectasia.

Authors:  Christoph Kuhm; Constanze Gallenmüller; Thilo Dörk; Moritz Menzel; Saskia Biskup; Thomas Klopstock
Journal:  J Neurol       Date:  2015-01-09       Impact factor: 4.849

5.  The pleiotropic movement disorders phenotype of adult ataxia-telangiectasia.

Authors:  Aurélie Méneret; Yara Ahmar-Beaugendre; Guillaume Rieunier; Nizar Mahlaoui; Bertrand Gaymard; Emmanuelle Apartis; Christine Tranchant; Sophie Rivaud-Péchoux; Bertrand Degos; Baya Benyahia; Felipe Suarez; Thierry Maisonobe; Michel Koenig; Alexandra Durr; Marc-Henri Stern; Catherine Dubois d'Enghien; Alain Fischer; Marie Vidailhet; Dominique Stoppa-Lyonnet; David Grabli; Mathieu Anheim
Journal:  Neurology       Date:  2014-08-13       Impact factor: 9.910

Review 6.  Ataxia telangiectasia syndrome: moonlighting ATM.

Authors:  Majid Zaki-Dizaji; Seyed Mohammad Akrami; Hassan Abolhassani; Nima Rezaei; Asghar Aghamohammadi
Journal:  Expert Rev Clin Immunol       Date:  2017-10-20       Impact factor: 4.473

Review 7.  Ataxia telangiectasia: more variation at clinical and cellular levels.

Authors:  A M R Taylor; Z Lam; J I Last; P J Byrd
Journal:  Clin Genet       Date:  2014-09-08       Impact factor: 4.438

8.  Dystonia as presenting manifestation of ataxia telangiectasia : a case report.

Authors:  V Goyal; M Behari
Journal:  Neurol India       Date:  2002-06       Impact factor: 2.117

9.  Cognitive phenotype in ataxia-telangiectasia.

Authors:  Franziska Hoche; Emily Frankenberg; Jennifer Rambow; Marius Theis; Jessica Ann Harding; Mayyada Qirshi; Kay Seidel; Eduardo Barbosa-Sicard; Luciana Porto; Jeremy D Schmahmann; Matthias Kieslich
Journal:  Pediatr Neurol       Date:  2014-05-05       Impact factor: 3.372

10.  Variant forms of ataxia telangiectasia.

Authors:  A M Taylor; E Flude; B Laher; M Stacey; E McKay; J Watt; S H Green; A E Harding
Journal:  J Med Genet       Date:  1987-11       Impact factor: 6.318

View more
  2 in total

1.  Clinical complications and their management in a child with ataxia-telangiectasia (A-T): A case report study.

Authors:  Marzieh Heidarzadeh Arani; Reza ArefNezhad; Javad Fathgharib; Asghar Aghamohammadi; Hossein Motedayyen
Journal:  Clin Case Rep       Date:  2020-11-29

2.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.